This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Covey, J. M. Articles by Kohn, K. W. Search for Related Content PubMed PubMed Citation Articles by Covey, J. M. Articles by Kohn, K. W.

Differences in DNA Damage Produced by Incorporation of 5-Aza-2'-deoxycytidine or 5,6-Dihydro-5-azacytidine into DNA of Mammalian Cells

Laboratory of Molecular Pharmacology [J. M. C., M. D'I, E. J. T., K. W. K.], and Developmental Therapeutics Program, Division of Cancer Treatment [J. M. C., M. D'I., E. J. T., D. S. Z., K. W. K.], National Cancer Institute, NIH, Bethesda, Maryland 20892

The effects of 5-aza-2'-deoxycytidine (aza-dCyd) and 5,6-dihydro-5-azacytidine (H₂-aza-Cyd) on the integrity of DNA from several mammalian cell lines were compared using the alkaline elution technique. While both compounds have been shown to inhibit DNA methylation, a direct comparison of their effects on DNA structure has not previously been reported. Exposure of L1210 cells to H₂-aza-Cyd (1–100 µg/ml) and simultaneous labeling with [¹⁴C]thymidine for 24 h resulted in the production of single-strand breaks in DNA, which were significantly repaired when cells were incubated in drug-free medium for an additional 24 h. This differed from our previous findings for aza-dCyd, confirmed here in parallel experiments, which showed that this compound produces alkali-labile lesions that persist for 48 h. The DNA effects of both drugs were significantly reduced when cells were prelabeled with [¹⁴C]thymidine, indicating that production of DNA lesions requires incorporation of the anomalous base. Studies utilizing pulse-labeled DNA indicated that aza-dCyd has little effect on the rate of DNA elongation, whereas H₂-aza-Cyd produced a complete inhibition for at least 6 h after drug removal. The contrasting pattern of DNA damage induced by these compounds in L1210 was also observed in two human lymphoblastoid cell lines, one of which was derived from a patient with xeroderma pigmentosum. We had previously concluded that alkali-labile sites in DNA from aza-dCyd-treated cells probably arise due to the chemical instability of aza-dCyd. In contrast, incorporated H₂-aza-Cyd is chemically stable. The singlestrand breaks produced in H₂-aza-Cyd treated cells were not of the alkalilabile type, and may represent an accumulation of DNA replication fragments and/or intermediates in an excision repair process. Thus, the DNA lesions produced by the two drugs have markedly different characteristics, and H₂-aza-Cyd should not be considered to be merely a stable pharmacological congener of aza-dCyd.

¹ To whom requests for reprints should be addressed, at Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, National Cancer Institute, NIH, Building 37, Room 5A19, Bethesda, MD 20892.

² On leave from Istituto di Ricerche Farmacologiche "Mario Negri," Milan Italy.

Received 6/ 3/85. Revised 4/24/86. Accepted 8/ 6/86.

This article has been cited by other articles:

				J. Xiong and R. J. Epstein Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status Mol. Cancer Ther., April 1, 2009; 8(4): 779 - 785. [Abstract] [Full Text] [PDF]

				H. Wang, Y. Zhao, L. Li, M. A. McNutt, L. Wu, S. Lu, Y. Yu, W. Zhou, J. Feng, G. Chai, et al. An ATM- and Rad3-related (ATR) Signaling Pathway and a Phosphorylation-Acetylation Cascade Are Involved in Activation of p53/p21Waf1/Cip1 in Response to 5-Aza-2'-deoxycytidine Treatment J. Biol. Chem., February 1, 2008; 283(5): 2564 - 2574. [Abstract] [Full Text] [PDF]

				W.-G. Zhu, T. Hileman, Y. Ke, P. Wang, S. Lu, W. Duan, Z. Dai, T. Tong, M. A. Villalona-Calero, C. Plass, et al. 5-Aza-2'-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation J. Biol. Chem., April 9, 2004; 279(15): 15161 - 15166. [Abstract] [Full Text] [PDF]

				N. Zeghari-Squalli, E. Raymond, E. Cvitkovic, and F. Goldwasser Cellular Pharmacology of the Combination of the DNA Topoisomerase I Inhibitor SN-38 and the Diaminocyclohexane Platinum Derivative Oxaliplatin Clin. Cancer Res., May 1, 1999; 5(5): 1189 - 1196. [Abstract] [Full Text] [PDF]